PerkinElmer, Inc. (PKI) Insider Sells $176,975.78 in Stock

PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,273 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $77.86, for a total transaction of $176,975.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Okun also recently made the following trade(s):

  • On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The stock was sold at an average price of $72.00, for a total transaction of $912,960.00.

PerkinElmer, Inc. (NYSE:PKI) traded down $0.23 during midday trading on Wednesday, reaching $75.77. 1,114,286 shares of the company’s stock traded hands, compared to its average volume of 664,132. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72. PerkinElmer, Inc. has a twelve month low of $52.25 and a twelve month high of $84.49. The stock has a market capitalization of $8,350.00, a price-to-earnings ratio of 53.74, a price-to-earnings-growth ratio of 1.73 and a beta of 0.76.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.03. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The business had revenue of $641.63 million during the quarter, compared to analyst estimates of $619.14 million. During the same period in the prior year, the business posted $0.83 earnings per share. The company’s revenue was up 13.2% on a year-over-year basis. equities analysts expect that PerkinElmer, Inc. will post 3.52 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Shareholders of record on Friday, April 13th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $0.28 annualized dividend and a yield of 0.37%. PerkinElmer’s payout ratio is 19.86%.

Several research analysts recently issued reports on the stock. Evercore ISI assumed coverage on shares of PerkinElmer in a research report on Wednesday, January 3rd. They issued an “in-line” rating and a $77.00 target price for the company. Bank of America upgraded shares of PerkinElmer from an “underperform” rating to a “neutral” rating and set a $78.00 target price for the company in a research report on Tuesday, December 19th. ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Robert W. Baird reiterated a “buy” rating and issued a $88.00 target price on shares of PerkinElmer in a research report on Friday, January 26th. Finally, Barclays upped their target price on shares of PerkinElmer from $69.00 to $73.00 and gave the stock an “underweight” rating in a research report on Friday, January 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $76.85.

A number of hedge funds and other institutional investors have recently bought and sold shares of PKI. Mutual of America Capital Management LLC boosted its position in PerkinElmer by 3.5% during the second quarter. Mutual of America Capital Management LLC now owns 13,470 shares of the medical research company’s stock valued at $918,000 after buying an additional 450 shares during the period. Balyasny Asset Management LLC purchased a new stake in PerkinElmer during the second quarter valued at about $271,000. AHL Partners LLP boosted its position in PerkinElmer by 180.6% during the second quarter. AHL Partners LLP now owns 50,495 shares of the medical research company’s stock valued at $3,441,000 after buying an additional 32,499 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its position in PerkinElmer by 37.5% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 25,886 shares of the medical research company’s stock valued at $1,763,000 after buying an additional 7,053 shares during the period. Finally, BlueCrest Capital Management Ltd purchased a new stake in PerkinElmer during the second quarter valued at about $440,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “PerkinElmer, Inc. (PKI) Insider Sells $176,975.78 in Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/07/perkinelmer-inc-pki-insider-sells-176975-78-in-stock.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply